Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Atripla to Stribild in HIV Patients
NCT02477527Phase 4Completed
- Sponsor
- Piedmont Columbus Regional Midtown
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Piedmont Columbus Regional Midtown. Primary endpoint: Percentage of Patients With Viral Loads < 50 at 24 weeks. Started Feb 2015; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02477527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477527.